Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Clinical Rheumatology
Published in: Clinical Rheumatology 8/2020

01-08-2020 | Colchicine | Letter to the Editor

Colchicine as a possible therapeutic option in COVID-19 infection

Authors: Rafael Parra-Medina, Juan Camilo Sarmiento-Monroy, Adriana Rojas-Villarraga, Edgar Garavito, Giovanni Montealegre-Gómez, Arley Gómez-López

Published in: Clinical Rheumatology | Issue 8/2020

Login to get access

Excerpt

Dear Editor, …
Literature
1.
Cumhur Cure M, Kucuk A, Cure E (2020) Colchicine may not be effective in COVID-19 infection; it may even be harmful? Clin Rheumatol:12–13
2.
Nuki G (2008) Colchicine: its mechanism of action and efficacy in crystal-induced inflammation. Curr Rheumatol Rep 10(3):218–227CrossRef
3.
Qin C, Zhou L, Hu Z, Zhang S, Yang S, Tao Y et al (2020) Dysregulation of immune response in patients with COVID-19 in Wuhan, China. Clin Infect Dis
4.
Martínez GJ, Celermajer DS, Patel S (2018) The NLRP3 inflammasome and the emerging role of colchicine to inhibit atherosclerosis-associated inflammation. Atherosclerosis. 269:262–271CrossRef
5.
Conti P, Ronconi G, Caraffa A, Gallenga C, Ross R, Frydas I et al (2020) Induction of pro-inflammatory cytokines (IL-1 and IL-6) and lung inflammation by Coronavirus-19 (COVI-19 or SARS-CoV-2): anti-inflammatory strategies. J Biol Regul Homeost Agents 34(2)
6.
Maurizi M, Delorme N, Laprévote-Heully MC, Lambert H, Larcan A (1986) Syndrome de détresse respiratoire aiguë de l’adulte au cours des intoxications par la colchicine. Ann Fr Anesth Reanim 5(5):530–532CrossRef
7.
Finkelstein Y, Aks SE, Hutson JR, Juurlink DN, Nguyen P, Dubnov-Raz G, Pollak U, Koren G, Bentur Y (2010) Colchicine poisoning: the dark side of an ancient drug. Clin Toxicol 48(5):407–414CrossRef
8.
Montealegre-Gómez G, Garavito E, Gómez-López A, Rojas-Villarraga A, Parra-Medina R (2020) Colchicine: a potential therapeutic tool against COVID-19. Experience of 5 patients. Reumatol Clín
9.
Dabbagh MF, Aurora L, D’Souza P, Weinmann AJ, Bhargava P, Basir MB (2020) Cardiac Tamponade secondary to COVID-19. JACC Case Rep
10.
Altschuler EL (2004) Colchicine for respiratory syncytial virus bronchiolitis. Lancet. 363(9424):1911CrossRef
11.
Lu N, Yang Y, Liu H, Ding X, Ou Y, Xia J et al (2019) Inhibition of respiratory syncytial virus replication and suppression of RSV-induced airway inflammation in neonatal rats by colchicine. 3 Biotech 9(11):392CrossRef
12.
Boulis NM, Willmarth NE, Song DK, Feldman EL, Imperiale MJ (2003) Intraneural colchicine inhibition of adenoviral and adeno-associated viral vector remote spinal cord gene delivery. Neurosurgery. 52(2):381–387CrossRef
13.
Bosem M, Harris R, Atherton SS. Optic nerve involvement in viral spread in herpes simplex virus type 1 retinitis. Invest Ophthalmol Vis Sci 1990;31(9):1683–1689
14.
Nouchi A, Monsel G, Lafon-Desmurs B, Meng L, Burrel S, Moyal-Barracco M, Caumes E (2018) Epstein-Barr virus-related acute genital ulcer successfully treated with colchicine. Acta Derm Venereol 98(1):134–135CrossRef
15.
Arrieta O, Rodriguez-Diaz JL, Rosas-Camargo V, Morales-Espinosa D, de Leon SP, Kershenobich D, Leon-Rodriguez E (2006) Colchicine delays the development of hepatocellular carcinoma in patients with hepatitis virus-related liver cirrhosis. Cancer. 107(8):1852–1858CrossRef
16.
Floreani, Lobello, Brunetto, Aneloni, Chiaramonte (1998) Colchicine in chronic hepatitis B: a pilot study. Aliment Pharmacol Ther 12(7):653–656CrossRef
Metadata
Title
Colchicine as a possible therapeutic option in COVID-19 infection
Authors
Rafael Parra-Medina
Juan Camilo Sarmiento-Monroy
Adriana Rojas-Villarraga
Edgar Garavito
Giovanni Montealegre-Gómez
Arley Gómez-López
Publication date
01-08-2020
Publisher
Springer International Publishing
Published in
Clinical Rheumatology / Issue 8/2020
Print ISSN: 0770-3198
Electronic ISSN: 1434-9949
DOI
https://doi.org/10.1007/s10067-020-05247-5

Other articles of this Issue 8/2020

Clinical Rheumatology 8/2020 Go to the issue

Clinical Image

Spotted bone disease

Case Based Review

Anti-cyclic citrullinated peptide antibody in the cerebrospinal fluid in patients with rheumatoid arthritis who have central nervous system involvement

Original Article

Serum amino acid metabolic profiles of ankylosing spondylitis by targeted metabolomics analysis

Correction

Correction to: Sustained improvement in work outcomes in employed patients with rheumatoid arthritis during 2 years of adalimumab therapy: an observational cohort study

Original Article

Clinical features and outcomes of the patients with anti-glycyl tRNA synthetase syndrome

Correction

Correction to: Clinical manifestations of Behçet’s disease in a large cohort of Chinese patients: gender- and age-related differences
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits